Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

[1]  Claude,et al.  Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. , 1991, The Journal of clinical investigation.

[2]  D. Monroe,et al.  Transmission of a procoagulant signal from tissue factor‐bearing cells to platelets , 1996, Blood Coagulation and Fibrinolysis.

[3]  J. Oliver,et al.  Active Site-inactivated Factors VIIa, Xa, and IXa Inhibit Individual Steps in a Cell-based Model of Tissue Factor-initiated Coagulation , 1998, Thrombosis and Haemostasis.

[4]  G. Feuerstein,et al.  Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[5]  D. Kirchhofer,et al.  A Human Antibody That Inhibits Factor IX/IXa Function Potently Inhibits Arterial Thrombosis Without Increasing Bleeding , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[6]  B. Sullenger,et al.  RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.

[7]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[8]  M. Hershfield,et al.  Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase , 2005, Arthritis research & therapy.

[9]  S. Steinhubl,et al.  First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity , 2006, Circulation.

[10]  M. Hershfield,et al.  Uricase and other novel agents for the management of patients with treatment-failure gout , 2007, Current rheumatology reports.

[11]  R. Becker,et al.  Factor IXa inhibitors as novel anticoagulants. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[12]  M. Hershfield,et al.  Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. , 2007, Arthritis and rheumatism.

[13]  R. Califf,et al.  Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. , 2008, American heart journal.

[14]  R. Becker,et al.  A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitor , 2008, Journal of thrombosis and haemostasis : JTH.

[15]  S. Steinhubl,et al.  Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease , 2008, Circulation.

[16]  R. Califf,et al.  Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.

[17]  R. Becker,et al.  First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention , 2010, Circulation.

[18]  S. Werns.  Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes , 2010 .

[19]  A Mukherjee,et al.  Nucleic acid aptamers: clinical applications and promising new horizons. , 2011, Current medicinal chemistry.

[20]  A. Bavry,et al.  Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. , 2011, Journal of the American College of Cardiology.

[21]  R. Becker,et al.  Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. , 2011, European heart journal.

[22]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[23]  J. Kasprzak,et al.  A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. , 2011, American heart journal.

[24]  S. Pocock,et al.  Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI , 2011, JACC. Cardiovascular interventions.

[25]  Seonghwan Lee,et al.  Aptamers and Their Biological Applications , 2012, Sensors.

[26]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction , 2013, Nature Reviews Cardiology.

[27]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[28]  J. Kasprzak,et al.  A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. , 2013, European heart journal.

[29]  J. Wower,et al.  Therapeutic RNA aptamers in clinical trials. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  S. Tope,et al.  Aptamers as therapeutics , 2013 .

[31]  M. Sabatine,et al.  Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials , 2014, The Lancet.